Login to Your Account

Affitech Bolsters Its Pipeline as It Moves Toward Development

By Cormac Sheridan

Wednesday, July 29, 2009
With a fundraising roadshow in the offing, Affitech A/S bolstered its pipeline by taking back in house a preclinical antivascular endothelial growth factor (VEGF) antibody development program it previously had licensed out to Peregrine Pharmaceuticals Inc. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription